Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Consolidated Net Income fell 11091.16% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 16005.72%. This contributed to the annual value of $673.7 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Consolidated Net Income is -$103.4 million, which was down 11091.16% from -$112.5 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Consolidated Net Income registered a high of $2.0 billion during Q1 2021, and its lowest value of -$112.5 million during Q2 2025.
  • Moreover, its 4-year median value for Consolidated Net Income was -$85.4 million (2023), whereas its average is $131.3 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first skyrocketed by 438287.33% in 2021, then plummeted by 11091.16% in 2025.
  • Over the past 4 years, Agios Pharmaceuticals' Consolidated Net Income (Quarter) stood at $4.0 million in 2021, then plummeted by 2524.56% to -$95.9 million in 2023, then decreased by 0.61% to -$96.5 million in 2024, then decreased by 7.16% to -$103.4 million in 2025.
  • Its Consolidated Net Income stands at -$103.4 million for Q3 2025, versus -$112.5 million for Q2 2025 and -$90.5 million for Q1 2025.